Children could be at risk of incorrect dosing due to a lack of information available to doctors in the country, according to an editorial published in the Canadian Medical Association Journal.
Doctors in Canada, Australia and Japan do not have access to the same level of pediatric research and drug information as their colleagues in the U.S. and Europe.
"Children are not little adults," said the authors. "Pediatric labeling should go well beyond simply adjusting adult doses to a pediatric weight, because this is inappropriate and potentially dangerous."
As an example, they mention the increased suicide risk from early off-label prescribing of selective serotonin reuptake inhibitors guided only by data in adults.
While drug companies claim there is not enough money in the pediatric market to make drug trials worthwhile, American and European governments provide financial incentives to encourage testing in children, and the U.S. Pediatric Research Equity Act requires drug companies to tests drugs and submit results.
"In line with recommendations of the World Health Organization, we need international harmonization of laws to ensure that appropriate incentives are in place to promote pediatric research necessary for pediatric indications and prescribing information," the authors concluded, calling upon Canadian policymakers to pass laws similar to those in the U.S.